To conclude, the findings of Bagley et al. demonstrate the safety of intraventricular administration of a bivalent CAR-T cell product targeting both EGFR and IL13Rα2 along with promising tumor responses (albeit not meeting objective response criteria per modified RANO criteria). The gene discussed is IL13RA2; the disease is neoplasm.